---
title: Natera CEO Steven Chapman Sells $39.5M in NTRA Stock — Six Insiders Unload $76.9M Combined
type: news
slug: natera-ceo-chapman-sells-39m-ntra-6-insiders-77m-feb-2026
canonical_url: https://13finsight.com/news/natera-ceo-chapman-sells-39m-ntra-6-insiders-77m-feb-2026
published_at: 2026-02-28T20:42:16.777Z
updated_at: 2026-02-28T20:42:18.292Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 465
locale: en
source: 13F Insight
---

# Natera CEO Steven Chapman Sells $39.5M in NTRA Stock — Six Insiders Unload $76.9M Combined

> Six Natera insiders sold $76.9M in NTRA stock in early February, led by CEO Chapman ($39.5M, $217M career). CFO Brophy sold $17.4M and Chief Legal Officer Rabinowitz sold $5.4M.

Six Natera insiders sold a combined $76.9 million in NTRA stock during late January and early February 2026, making it one of the largest coordinated insider selling events in the biotech sector this year. CEO Steven Chapman led with $39.5 million — bringing his career insider sales to an extraordinary $217 million. $76.9M Across Six Insiders Insider Title Transactions Value Career Sales Shares After Steven Chapman CEO & President 11 $39.45M $217.0M 123,156 Michael Brophy Chief Financial Officer 11 $17.41M $79.2M 52,120 Solomon Moshkevich Pres., Clinical Diagnostics 11 $7.12M $29.9M 137,847 John Fesko President, Chief Biz Officer 6 $5.50M $11.9M 175,540 Daniel Rabinowitz Sec. & Chief Legal Officer 5 $5.38M $27.8M 223,813 Jonathan Sheena Co-Founder 14 $2.02M $88.6M 21,782 Total: 6 insiders, 58 transactions $76.88M $454M CEO Chapman: $217M Career Seller Steven Chapman's $217 million in career insider sales places him among the most prolific insider sellers in all of biotech. His latest $39.5M sale across 11 transactions at $230-$234 per share was methodical — executed over multiple days in early February. Chapman retains 123,156 shares worth approximately $28 million. For perspective, he's sold nearly 8x the value of his current position over his career. The CEO's ongoing liquidation pattern has been consistent across NTRA's rise from a niche prenatal testing company to a $16 billion market cap genomics leader. CFO Brophy: $79.2M in Career Sales CFO Michael Brophy mirrored the CEO with 11 transactions totaling $17.41M. His $79.2M in career sales is remarkable for a CFO, and his remaining 52,120 shares (~$12M) means he's sold over 6x his current holdings. The finance chief's aggressive monetization adds weight to the bearish interpretation. Co-Founder Sheena: $88.6M Sold, 21,782 Shares Left Co-founder Jonathan Sheena has sold $88.6 million in NTRA stock and retains just 21,782 shares (~$5M). His 14 transactions for $2.02M in this round represent one of his smaller recent selling windows, but the career context is unmistakable — the co-founder's remaining position is a small fraction of what he's monetized. Collective Career: $454 Million Sold Together, these six insiders have sold $454 million in Natera stock. That's roughly 3% of the company's entire current market capitalization — monetized from insider positions alone. The scale of cumulative selling is extraordinary even by high-growth biotech standards. 58 total transactions in a ~2 week window $76.9M combined — largest biotech insider sell of early 2026 CEO at $217M career — relentless, consistent selling All sold at $225-$234 — tight range near recent highs $454M cumulative — these six have sold half a billion in NTRA For NTRA investors, the ongoing pattern is clear: Natera's leadership has been systematically converting stock into cash at every opportunity. The $76.9M February sell isn't unusual for this group — it's routine. And that consistency may be the most telling signal of all.

---

Source: 13F Insight — https://13finsight.com/news/natera-ceo-chapman-sells-39m-ntra-6-insiders-77m-feb-2026
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-02-28T20:42:18.292Z